Phase 2 Trial of TAK-228 for PI3K-dysregulated Sarcoma

Share this content:
Researchers are evaluating whether TAK-228, a novel, orally administered mTOR inhibitor, is efficacious among patients with unresectable or metastatic soft tissue sarcoma.
Researchers are evaluating whether TAK-228, a novel, orally administered mTOR inhibitor, is efficacious among patients with unresectable or metastatic soft tissue sarcoma.

Title: Phase II Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas With Dysregulation of the mTOR Pathway1

Description: For this single arm, phase 2 study, researchers are evaluating whether TAK-228, a novel, orally administered mTOR inhibitor, is an efficacious therapy among patients with unresectable or metastatic soft tissue sarcoma.

Patients must be at least 18 years old, have disease displaying PI3K pathway dysregulation, and be refractory to at least 1 prior therapy, excluding neoadjuvant/adjuvant therapy “in a curative setting.”

Patients will receive 3 mg of the experimental medicine daily for 21 days per cycle.

The primary outcome is progression-free survival among patients with PI3K/AKT/mTOR pathway dysregulation; secondary outcomes include toxicity rates, overall response rate, and overall survival.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02987959.

Status: This study is open and recruiting participants as of April 17, 2017.

This study is sponsored by Fox Chase Cancer Center.

Reference

  1. Clinicaltrials.gov. Study of TAK-228 (MLN0128) in soft tissue sarcomas. NCT02987959. https://clinicaltrials.gov/ct2/show/NCT02987959. Accessed April 17, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters